Q tit ti h i l i h t i ti f d i l tQuantitative neurophysiologic characterization of a paradoxical response toQuantitative neurophysiologic characterization of a paradoxical response toQuantitative neurophysiologic characterization of a paradoxical response to541 6 541 6Quantitative neurophysiologic characterization of a paradoxical response to 541 6 541 6Q p y g p p541.6 541.6
l id i l b i i j d h bj tzolpidem in a severely brain injured human subjectzolpidem in a severely brain-injured human subjectzolpidem in a severely brain injured human subjectp y j jS 1 C 1 1 2 1 S ff1S T Williams1 M M Conte1 E J Kobylarz1 J E Hersh2 J D Victor1 N D Schiff1S T Williams1 M M Conte1 E J Kobylarz1 J E Hersh2 J D Victor1 N D Schiff1S. T. Williams , M. M. Conte , E. J. Kobylarz , J. E. Hersh , J. D. Victor , N. D. Schiff, , y , , ,
1D t t f N l d N i d 2D t t f P bli H lth W ill C ll M di l C ll N Y k NY1Department of Neurology and Neuroscience and 2Department of Public Health Weill Cornell Medical College New York NYDepartment of Neurology and Neuroscience and Department of Public Health, Weill Cornell Medical College, New York, NYp gy p , g , ,
PURPOSE Pl h ldMETHODSPURPOSE PlaceholderMETHODSPURPOSE PlaceholderMETHODS• 24 hr continuous video EEGData Collection & AnalysisTo explore the spectral and coherence characteristics of the Subject• 24 hr continuous video EEGData Collection & AnalysisTo explore the spectral and coherence characteristics of the Subject
• 200Hz sampling rate
ySi l bj t bli d d t d
p p
paradoxical arousal response to zolpidem after severe brain injury
j32 ld l d i 9 i• 200Hz sampling rate• Single subject, unblinded studyparadoxical arousal response to zolpidem after severe brain injury. • 32 year old male, near drowning 9 years prior
• Longitudinal bipolar montage (International 10-20 system)g j , y
S bj t d itt d t i ti t l it
p p p j y y , g y p
S h i b i i j MCS f 2• Longitudinal bipolar montage (International 10-20 system)• Subject admitted to inpatient neurology unit • Severe hypoxic brain injury; MCS for >2 years• XLTEK data acquisition system (XLTEK Ontario)
Subject admitted to inpatient neurology unit Severe hypoxic brain injury; MCS for 2 yearsXLTEK data acquisition system (XLTEK, Ontario)
• Maintained home zolpidem doseBACKGROUND • MRI: Left thalamic lesion• Two- and three-second EEG segments with minimal artifact
Maintained home zolpidem doseBACKGROUND MRI: Left thalamic lesion
Overview:• Two- and three-second EEG segments with minimal artifact
• 10mg crushed in solution by mouth via syringeBACKGROUND
• Arousal response to zolpidem discovered incidentally by motherOverview:identified
10mg crushed, in solution by mouth via syringe • Arousal response to zolpidem discovered incidentally by mother
Zolpidem is commonly used to induce sleep in healthy adultsidentified• Every 3-5 hours during day• Zolpidem is commonly used to induce sleep in healthy adults.
• Power & coherence spectra estimated using five SlepianEvery 3 5 hours during day
18FDG PET OFF d ON l idp y p y
P d i l l b d i b i i j d• Power & coherence spectra estimated using five Slepian• 18FDG-PET OFF and ON zolpidem• Paradoxical arousal response observed in some brain-injured
p g p
f ti t 7FDG PET OFF and ON zolpidem
Sample EEG Segments Selected for Analysis. Observed BehaviorObserved BehaviorZolpidem 10mg dosesParadoxical arousal response observed in some brain injured
ti t th h i l i l b i f hi h i kfunctions as tapers7Sample EEG Segments Selected for Analysis.
Red = Hour before dose Blue = Hour after dose Observed BehaviorObserved BehaviorZolpidem 10mg dosesD f hi h ltpatients the physiological basis for which is unknown
functions as tapersRed = Hour before dose, Blue = Hour after dose.
ON
Observed BehaviorObserved BehaviorDoses for which results
t di l dpatients, the physiological basis for which is unknown. ONOFFOFF Z l id ON Z l id
are not displayed
• Prior study in akinetic mute patient shows increased metabolism in TimelineOFF
OFF Zolpidem ON Zolpidem• Prior study in akinetic mute patient shows increased metabolism in Timeline OFF ZolpidemAO 2 ( lf l ti )
ON ZolpidemI d b l fl & i l imedial frontal cortex thalami and postrolandic regions after Ad t EEG di B f d
AOx2 (self, location) Improved verbal fluency & articulation08:10 08:29medial frontal cortex, thalami and postrolandic regions after Adequate EEG recordings Before andAOx2 (self, location)
D th iImproved verbal fluency & articulation
Sh t d l t f t10 00
08 012:1312:00
08:29
Video EEG Recordingsp g
zolpidem1q g
After olpidem administration ereDysarthria Shortened latency of motor responses10:00 16:24
12:1316:54
12:0016:0016:38
Video EEG Recordings
zolpidem1 After zolpidem administration were y
Dysphagiay p
Abl t f d ll
16:00p
N t d t d t EEG & PET h t i ti f th
p
available for Days 2 3 and 5Dysphagia Able to feed orally
• No study to date compares EEG & PET characteristics of the available for Days 2,3 and 5y p g
L hemiparesis spasticityy
Reduced spasticityNo study to date compares EEG & PET characteristics of the
l t l id i b i i j i h
yL hemiparesis, spasticity Reduced spasticity
arousal response to zolpidem in severe brain injury in humansy
LUE: flexor posturingp y
Smooth goal directed movementsDay 1 Day 2 Day 3 Day 4 Day 5 Day 6arousal response to zolpidem in severe brain injury in humans. LUE: flexor posturing Smooth, goal-directed movementsDay 1 Day 2 Day 3 Day 4 Day 5 Day 6
Ab t B i I j RUE: 1-1 5Hz resting tremor Elimination of resting tremorAbout Brain Injury: RUE: 1-1.5Hz resting tremor Elimination of resting tremor00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00About Brain Injury:
2 LLE & RLE: extensor posturing Object manipulation00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00 08:00 16:00 00:00
• Over 1 4 million cases annually 2 LLE & RLE: extensor posturing Object manipulation Over 1.4 million cases annually.
RESULTS (pen spoon baseball)• Etiologies: head trauma cerebrovascular events seizure RESULTS (pen, spoon, baseball)• Etiologies: head trauma, cerebrovascular events, seizure, RESULTS
cardiopulmonary insufficiency intracranial masses infectious orcardiopulmonary insufficiency, intracranial masses, infectious or p y y, ,
inflammatory diseases metabolic disorders toxic ingestionsinflammatory diseases, metabolic disorders, toxic ingestions. Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemy , , g
R f i ti ft i j i t l 3 Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & AfterPower Spectra: Before & After ZolpidemZolpidem• Recovery of communication years after injury is extremely rare.3
Power Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidem Power Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidemPower Spectra: Before & After Power Spectra: Before & After ZolpidemZolpidemRecovery of communication years after injury is extremely rare.
(Day 2 Afternoon Dose)(Day 2 Afternoon Dose)(Day 2 Afternoon Dose)(Day 2 Afternoon Dose) (Day 3 Afternoon Dose)(Day 3 Afternoon Dose)(Day 3 Afternoon Dose)(Day 3 Afternoon Dose) (Day 5 Morning Dose)(Day 5 Morning Dose)(Day 5 Morning Dose)(Day 5 Morning Dose)(Day 2, Afternoon Dose)(Day 2, Afternoon Dose)(Day 2, Afternoon Dose)(Day 2, Afternoon Dose) (Day 3, Afternoon Dose)(Day 3, Afternoon Dose)(Day 3, Afternoon Dose)(Day 3, Afternoon Dose) (Day 5, Morning Dose)(Day 5, Morning Dose)(Day 5, Morning Dose)(Day 5, Morning Dose)C iti F ti (Day 2, Afternoon Dose)(Day 2, Afternoon Dose)(Day 2, Afternoon Dose)(Day 2, Afternoon Dose) (Day 3, Afternoon Dose)(Day 3, Afternoon Dose)(Day 3, Afternoon Dose)(Day 3, Afternoon Dose) (Day 5, Morning Dose)(Day 5, Morning Dose)(Day 5, Morning Dose)(Day 5, Morning Dose)Cognitive Function
10Fz-Cz
10Fz-Cz
10Fz-Cz
10Fz-Cz
5Fz-Cz
5Fz-Cz
functional10
7 67HBefore
10
7 67HBefore
10Before
10Before
5
8 50HzBefore
5
8 50HzBeforefunctional
i ti5
7.67HzAfter5
7.67HzAfter 5 After5 After 0
8.50Hz
22.33Hz After08.50Hz
22.33Hz After
communication 023.67Hz
023.67Hz
0 7.00Hz 24.33Hz0 7.00Hz 24.33Hz55
-5-5 -5-5
-5-5
10
-5
B)
10
-5
B)
10
-5
B)
10
-5
B) -10
B) -10
B)
5F3-C3
5F3-C3 -10
er(
dB
-10
er(
dB
10F4-C4
10F4-C4 -10
er(
dB
-10
er(
dB
10F4-C4
10F4-C4
5F3-C3
5F3-C3
-15er(
dB
-15er(
dB
5F4-C4
5F4-C4
20F3-C3
20F3-C3
5Before
5Before -15
Pow
e
-15
Pow
e 10Before
10Before -15
Pow
e
-15
Pow
e 10Before
10Before
5Before
5Before
15
Pow
e 15
Pow
e 5
8 00Hz 24.33Hz Before5
8 00Hz 24.33Hz Before20
Before20
Before
7.67Hz23 67Hz
After7.67Hz23 67Hz
After-20
P
-20
P
57 67Hz
After57 67Hz
After-20
P
-20
P 5 After5 After07.67Hz 24.67Hz
After07.67Hz 24.67Hz
After -20P -20P
08.00Hz 24.33Hz
After08.00Hz 24.33Hz
After10
After10
After
FullSevere to0
23.67Hz0
23.67Hz
2525 0
7.67Hz
25.33Hz0
7.67Hz
25.33Hz2525
07 67Hz
26.00Hz0
7 67Hz
26.00Hz
-5
24.67Hz
-5
24.67Hz
-25-25 -5-5
10
8.50Hz
10
8.50HzFullSevere to -25-25 00 -25-25
-5
7.67Hz
-5
7.67Hz55
3030
55
022.33Hz
022.33Hz
RecoveryModerate -5
dB
) -5
dB
) -30-30 -5
dB
) -5
dB
) -30-30
10
5
dB
)
10
5
dB
)-10
dB
) -10
dB
) -30-30 -10
dB
) -10
dB
)
0
dB
)
0
dB
)
RecoveryModerate
C iti
M
er(
de
r(d
0 20 40 60 80 100-35
0 20 40 60 80 100-35 -10e
r(d
-10er(
d
0 20 40 60 80 100-35
0 20 40 60 80 100-35
-10
er(
d -10
er(
d
-15er(
d
-15er(
d
0 20 40 60 80 100-35
0 20 40 60 80 100-35 -15e
r(d
-15er(
d
-10er(
d
-10er(
d
Cognitive
Mo
-10Pow
-10Pow 0 20 40 60 80 100
Frequency(Hz)0 20 40 60 80 100
Frequency(Hz)15P
ow
15Pow 0 20 40 60 80 100
Frequency(Hz)0 20 40 60 80 100
Frequency(Hz)-15
Pow -15
Pow
20Pow
20Pow 0 20 40 60 80 100
Frequency(Hz)0 20 40 60 80 100
Frequency(Hz)20P
ow
20Pow
Pow
PowCognitive
Di bilit
to 10P 10P -15P -15P
-20
P
-20
P-20P -20P -20P -20P
-20
P
-20
P
i t t l di t dDisability
or
1515-20-20
-25-25-25-25 -25-25
consistent goal-directedy F
u -15-15
2525 30
25
30
25
3030 3030-30-30
functional movements
un -25-25 -30-30-30-30 -30-30
functional movements nc
0 20 40 60 80 100-20
0 20 40 60 80 100-20
0 20 40 60 80 100-30
0 20 40 60 80 100-30
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-40
0 20 40 60 80 100-40c
tio
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)
0 20 40 60 80 100Frequency(Hz)o
n
VS
n
VS LIS*MCSVS LIS*MCS(PVS)
LISMCST6 O2T6 O2T5 O1T5 O1 T6 O2T6 O2T5 O1T5 O1 T6 O2T6 O2T5 O19 00Hz T5 O19 00Hz
(PVS) 10T6-O2
10T6-O2
10T5-O1
10T5-O1
10T6-O2
10T6-O2
10T5-O1
10T5-O1
10T6-O2
9 50Hz10T6-O2
9 50Hz5T5-O19.00Hz
5T5-O19.00Hz
(PVS)5
Before
Aft5
Before
Aft5
Before
Aft5
Before
Aft 5Before
Aft5Before
Aft5Before
Aft5Before
Aft 5
9.50HzBefore
Aft5
9.50HzBefore
Aft0
Before
Aft0
Before
Aft5 After5 After5
8 00Hz
After5
8 00Hz
After 5 After5 After5 After5 After 5 After5 After0 After0 After
0 8.00Hz0 8.00Hz08.00Hz
08.00Hz
010.00Hz
010.00Hz
0 10.00Hz0 10.00Hz 00-5 22.67Hz-5 22.67Hz
C 5555-5 22.33Hz-5 22.33Hz-5
22 00Hz-5
22 00Hz 5
21.67Hz
5
21.67Hz
1010Coma Cz-PzCz-Pz
-5
dB
) -5
dB
)-5
dB
) 24.33Hz-5
dB
) 24.33Hz
-10dB
)
-10dB
)
-10dB
) 22.00Hz
-10dB
) 22.00Hz
Cz-PzCz-Pz
-5
dB
) -5
dB
)-10
dB
) -10
dB
)
Cz-PzCz-PzComa10
Cz Pz
B f10
Cz Pz
B f
-10
we
r( -10
we
r(-10
we
r( -10
we
r(
15
10
we
r(
15
10
we
r(
15
10
we
r(
15
10
we
r(
10Cz Pz
B f10
Cz Pz
B f
-10
we
r( -10
we
r(-15
we
r( -15
we
r(
5Cz Pz
8 50HzB f
5Cz Pz
8 50HzB f
5Before
After5Before
After -15Pow
-15Pow
-15Pow
-15Pow -15
Pow -15
Pow-15
Pow -15
Pow
5Before
After5Before
After -15Pow
-15Pow
-20Pow
-20Pow
0
8.50HzBefore
After0
8.50HzBefore
After
VS: Vegetative State PVS: Persistent Vegetative State MCS: Minimally Conscious State 0
58.33Hz
After
0
58.33Hz
After 15151515-20-20-20-20
0
5 After
0
5 After 15152020 022.67Hz
After022.67Hz
After
VS: Vegetative State. PVS: Persistent Vegetative State. MCS: Minimally Conscious State. 4
024.00Hz
024.00Hz
-20-20-20-20-25-25-25-25
09.00Hz 23.33Hz
09.00Hz 23.33Hz -20-20-25-25 -5-5
LIS: Locked-In Syndrome (*not a disorder of consciousness). Adapted from Schiff, 20044 -5
)
-5
) -25-25-25-25 -30-30-30-30-5
)
-5
) -25-25-30-30 -10) -10)y ( ) p ,-10(d
B)
-10(dB
)
30303030 35
30
35
30
35
30
35
30
-10(dB
)
-10(dB
)
30303535
10
(dB
) 10
(dB
)
About Zolpidem: -15we
r(
-15we
r(
0 20 40 60 80 100-30
0 20 40 60 80 100-30
0 20 40 60 80 100-30
0 20 40 60 80 100-30
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
0 20 40 60 80 100-35
-15we
r(
-15we
r(
0 20 40 60 80 100-30
0 20 40 60 80 100-30
0 20 40 60 80 100-35
0 20 40 60 80 100-35 -15
we
r( -15
we
r(
About Zolpidem:20
-15
Pow
20
-15
Pow
Frequency(Hz)Frequency(Hz)Frequency(Hz)Frequency(Hz) Frequency(Hz)Frequency(Hz)Frequency(Hz)Frequency(Hz)
20
-15
Pow
20
-15
Pow
Frequency(Hz)Frequency(Hz)Frequency(Hz)Frequency(Hz)-20P
ow
-20Pow
• Imidazopyridine GABA A1 receptor agonist-20-20 -20-20
2525• Imidazopyridine GABA-A1 receptor agonist -25-25 -25-25-25-25py p g
• Trade names: Ambien® Stilnoct® Myslee® Noctidem and others-30-30 -30-30 -30-30
• Trade names: Ambien®, Stilnoct®, Myslee®, Noctidem and others3535 3535 3535
, , y ,
M i l t ti 1 6 h ft d i i t ti0 20 40 60 80 100
-35
Freq enc (H )0 20 40 60 80 100
-35
Freq enc (H )0 20 40 60 80 100
-35
Freq enc (H )0 20 40 60 80 100
-35
Freq enc (H )0 20 40 60 80 100
-35
Freq enc (H )0 20 40 60 80 100
-35
Freq enc (H )• Maximum plasma concentration 1.6 hours after administration Frequency(Hz)Frequency(Hz) Frequency(Hz)Frequency(Hz) Frequency(Hz)Frequency(Hz)Maximum plasma concentration 1.6 hours after administration
H lf lif 2 4 h (i h lth bj t )5• Half life = 2 4 hours (in healthy subjects)5 Average % PowerAverage % PowerHalf life 2.4 hours (in healthy subjects) Average % Power Average % Power
Ab t EEG P & C h S t DISCUSSION Decrease at 7 67HzDecrease at 7 67HzAbout EEG Power & Coherence Spectra: DISCUSSION Decrease at 7.67HzDecrease at 7.67HzAbout EEG Power & Coherence Spectra:
C hC hDISCUSSION
100%
• Power spectra used to estimate the relative contributions of each CoherenceCoherence Findings Possible Mechanisms100%
Power spectra used to estimate the relative contributions of each CoherenceCoherence Findings Possible Mechanisms cortex 71%80%
frequency to overall composition of a time varying EEG signal (D 2)(D 2)g
OFF Z l id A ibl h i l i l b i f th h i EEGcortex 71%
66% 63% 65%80%
frequency to overall composition of a time-varying EEG signal (Day 2)(Day 2) OFF Zolpidem: A possible physiological basis for the change in EEG 56% 59%63% 65%
60%
• Power content of each frequency band changes with arousal state(Day 2)(Day 2) O o p de
D f ti l i ti d t t l ith
poss b e p ys o og ca bas s o t e c a ge G
t i i d ti ti f f t l t
56%60%
• Power content of each frequency band changes with arousal state( y )( y )
Dysfunctional communication and motor control with: power spectra is increased activation of frontal systems 40%q y g
Coherence between regions suggests correlated activityDysfunctional communication and motor control, with:
18
power spectra is increased activation of frontal systems th l
40%
• Coherence between regions suggests correlated activity • Global hypometabolism (L>R) on 18FDG-PET mediating executive and pre-motor function via release thalamus20%
g gg y
M b d t t bli h i ft b i i j 6Global hypometabolism (L>R) on FDG PET mediating executive and pre motor function, via release
striatum20%
• May be used to establish prognosis after severe brain injury6• Narrow aberrant EEG spectral peaks in 7 11Hz of thalamocortical outflow
striatumMay be used to establish prognosis after severe brain injury • Narrow, aberrant EEG spectral peaks in 7-11Hz of thalamocortical outflow. 0%
range globally ti tiglobus F3-C3 T5-O1 Fz-Cz Cz-Pz F4-C4 T6-O2range globally As a GABA-A1 agonist zolpidem may inhibit theactivationglobus F3 C3 T5 O1 Fz Cz Cz Pz F4 C4 T6 O2
PET I OFF d ONPET I OFF d ON Z l idZ l idg g y
Intermittent spectral peaks at 70 80HzAs a GABA-A1 agonist, zolpidem may inhibit the inhibitionpallidus The bars represent the mean percent decrease in
PET Images OFF and ONPET Images OFF and ON ZolpidemZolpidem • Intermittent spectral peaks at 70-80Hz GABA sensitive neurons of the globus pallidus interna zolpidemzolpidem??pallidus
internaThe bars represent the mean percent decrease in
t 7 67H d th 3 d i thPET Images OFF and ON PET Images OFF and ON ZolpidemZolpidem p p
P k i l l h i 5 15HGABA-sensitive neurons of the globus pallidus interna zolpidemzolpidem??
interna power at 7.67Hz, averaged over the 3 doses in the gg pp• Peak in local coherence in 5-15Hz range
g p
(GPi) thus removing their tonic inhibition of the thalamusp g
panels above Black = Left hemisphere White =Peak in local coherence in 5 15Hz range (GPi), thus removing their tonic inhibition of the thalamus Adapted from Schiff (2009)13panels above. Black Left hemisphere, White
Right hemisphere Gray Midline
Th OFF t t l f k ( t 7 11H )
( ), g
d l ti ti t i t llid th l ti lAdapted from Schiff (2009) Right hemisphere, Gray = Midline.
Global metabolism increased ~2 fold The OFF state low frequency peak (at 7-11Hz) may and upregulating cortico-striato-pallido-thalamo-corticalGlobal metabolism increased 2 fold. The OFF state low frequency peak (at 7 11Hz) may
l h l i di i h i i h i
and upregulating cortico striato pallido thalamo cortical
k ( fi ) 8 10 A di ff i l REFERENCEScorrelate to pathologic conditions: hypoxic-ischemic networks (see figure) 8-10 A direct effect on cortical REFERENCES% Change in correlate to pathologic conditions: hypoxic ischemic networks (see figure). A direct effect on cortical
1 Brefel-Courbon C Payoux P Ory F Sommet A Slaoui T Raboyeau G Lemesle B Puel M Montastruc JL Demonet JF Cardebat D Clinical and Imaging Evidence of Zolpidem Effect in% Change in encephalopathy alpha coma thalamic deafferentation inhibitory interneuronal networks likely also contributes
1. Brefel Courbon C, Payoux P, Ory F, Sommet A, Slaoui T, Raboyeau G, Lemesle B, Puel M, Montastruc JL, Demonet JF, Cardebat D. Clinical and Imaging Evidence of Zolpidem Effect in
Hypoxic Encephalopathy Ann Neurol 2007; 62: 102-105
% g
M SUV* encephalopathy, alpha coma, thalamic deafferentation. inhibitory interneuronal networks likely also contributes Hypoxic Encephalopathy. Ann Neurol 2007; 62: 102-105.
2 Langlois JA Rutland Brown W Thomas KE Traumatic brain injury in the United States: emergency department visits hospitalizations and deaths Atlanta (GA): Centers for DiseaseMean SUV*OFF to the observed effects 11
2. Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease
Control and Prevention Nation Center for Injury Prevention and Control; 2006
Mean SUVOFF ON Zolpidem: to the observed effects.11 Control and Prevention, Nation Center for Injury Prevention and Control; 2006.
3 S hiff ND M d li th i i ll i t t t f b i f ti d th ti ibiliti P i B i R h 2005 150 477 497Region Left RightOFF ON Zolpidem: 3. Schiff ND. Modeling the minimally conscious state: measurements of brain function and therapeutic possibilities. Progress in Brain Research 2005;150:477-497.
4 S hiff ND Th l f i i d i h ll f iti i I G i MS d Th C iti N i 3 d d B t MIT P 2004
Region Left Right
Improved communication and motor control with: This model predicts increased metabolism in the4. Schiff ND. The neurology of impaired consciousness: challenges for cognitive neuroscience. In: Gazzaniga MS ed. The Cognitive Neurosciences, 3rd ed. Boston: MIT Press; 2004.
Mesial frontal 139% 146% Improved communication and motor control, with: This model predicts increased metabolism in the 5. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865-889.Mesial frontal 139% 146%
• Increases in regional & global metabolism thalamus striatum and frontal cortex and decreased6. Davey MP, Victor JD, Schiff ND. Power spectra and coherence in the EEG of a vegetative patient with severe asymmetric brain damage. Clin Neurophys 2000;111:1949-1954.
Lateral frontal 166% 183% • Increases in regional & global metabolism thalamus, striatum and frontal cortex and decreased y p g p y g p y
7. Mitra PP, Pesaren B. Analysis of dynamic brain imaging data. Biophysical Journal 1999; 76: 691-708.Lateral frontal 166% 183% g g
L f b t t l k i 7 11H
,
t b li i th GPi d t th t ti l, y y g g p y ;
8. Schiff, ND, Ribary, U, Moreno, D, Beattie, B, Kronberg, E, Blasberg, R, Giacino, J, McCagg, C, Fins, JJ, Llinas, R and Plum, F. Residual cerebral activity and behavioral fragments in the
C l i 145% 153% • Loss of aberrant spectral peaks in 7-11Hz range metabolism in the GPi and suggests other potential 8. Schiff, ND, Ribary, U, Moreno, D, Beattie, B, Kronberg, E, Blasberg, R, Giacino, J, McCagg, C, Fins, JJ, Llinas, R and Plum, F. Residual cerebral activity and behavioral fragments in the
persistent vegetative state Brain 2002;125 1210-1234Calcarine 145% 153% oss o abe a t spect a pea s a ge
D d hifti f 70 80H k
etabo s t e G a d suggests ot e pote t a
t t f th ti i t ti hi h h h dpersistent vegetative state. Brain 2002;125, 1210 1234.
9 Schiff ND Rodriguez-Moreno D Kamal A Petrovich N Giacino J Plum F and Hirsch J fMRI reveals large-scale network activation in minimally conscious patients Neurology
Calcarine 145% 153%
S % % • Downward shifting of 70-80Hz peaks targets for therapeutic intervention which have had9. Schiff ND, Rodriguez-Moreno D, Kamal A, Petrovich N, Giacino J, Plum F and Hirsch J. fMRI reveals large-scale network activation in minimally conscious patients. Neurology
2005;64:514 523Striatum 156% 156% Downward shifting of 70 80Hz peaks targets for therapeutic intervention, which have had 2005;64:514-523.
10 Schiff ND Posner JB Another “Awakenings” Ann Neurol 2007;62:5 7Striatum 156% 156%
ON • Reduction in local coherence in 5-15Hz range empiric success:10. Schiff ND, Posner JB. Another Awakenings . Ann Neurol. 2007;62:5-7.
11 McCarth MM Bro n EN Kopell N Potential net ork mechanisms mediating electroencephalographic beta rh thm changes d ring propofol ind ced parado ical e citation JThalamus 148% 127%ON Reduction in local coherence in 5 15Hz range empiric success: 11. McCarthy MM, Brown EN, Kopell N. Potential network mechanisms mediating electroencephalographic beta rhythm changes during propofol –induced paradoxical excitation. J
N i 2008 28 13488 13504Thalamus 148% 127%
• Dopaminergic agents support the function of striatalNeurosci. 2008;28:13488-13504.
The ON state behaviors reflected normalization of • Dopaminergic agents support the function of striatal 12. Schiff ND, Giacino JT, Kalmar K, Victor JD, Baker K, Gerber M, Fritz B, Eisenberg B, Biondi T, O'Connor J, Kobylarz EJ, Farris S, Machado A, McCagg C, Plum F, Fins JJ, Rezai AR.Peaks in short-range coherence noted in The ON state behaviors reflected normalization of medium spiny neurons
Behavioural improvements with thalamic stimulation after severe traumatic brain injury. Nature 2007; 448: 600-603.Peaks in short range coherence noted in
5 15Hz frequency range which are*SUV S d di d U k V l integrative function that is dependent on circuit-level medium spiny neurons. 13. Schiff ND. An integrative research paradigm for the cognitive neuroscience of consciousness. In: Gazzaniga MS ed. The Cognitive Neurosciences, 4th ed. Boston: MIT Press; 2009.5-15Hz frequency range, which are *SUV = Standardized Uptake Value integrative function that is dependent on circuit-level p y
Thalamic DBS directly activates thalamostriatal and Support: The Rockefeller University Clinical and Translational Science Center Clinical Scholars Program (STW) The Charles A Dana Foundation (NDS) The
g p g g g g
reduced after zolpidem administration.SUV Standardized Uptake Value
mechanisms • Thalamic DBS directly activates thalamostriatal and Support: The Rockefeller University Clinical and Translational Science Center, Clinical Scholars Program (STW), The Charles A. Dana Foundation (NDS), The
J S M D ll F d ti (NDS) d NIH HD 91512 (NDS) W th k B dl B tti f tit ti l i f th PET i Pl di t
p
mechanisms. y
th l ti l tfl 12James S. McDonnell Foundation (NDS), and NIH HD 91512 (NDS). We thank Bradley Beattie for quantitative analysis of the PET images. Please direct
thalamocortical outflow.12 correspondence to [email protected] outflow. p q @g
Top Related